LeonaBio, Inc.
$9.38
▲
13.27%
2026-04-21 07:57:00
leonabio.com
NCM: LONA
Explore LeonaBio, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$83.23 M
Current Price
$9.38
52W High / Low
$14.21 / $2.2
Stock P/E
—
Book Value
$5.2
Dividend Yield
—
ROCE
-76.55%
ROE
-2.91%
Face Value
—
EPS
$-24.7
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
19
Beta
2.23
Debt / Equity
2.89
Current Ratio
1.88
Quick Ratio
1.88
Forward P/E
—
Price / Sales
—
Enterprise Value
$3.5 M
EV / EBITDA
-0.1
EV / Revenue
—
Rating
Buy
Target Price
$16
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Zevra Therapeutics, Inc. | $10.78 | 7.23 | $601.51 M | — | -1.72% | 85.66% | $13.16 / $6.85 | $2.72 |
| 2. | Whitehawk Therapeutics, Inc. | $4.23 | — | $193.98 M | — | -83.93% | -21.82% | $4.48 / $1.39 | $2.89 |
| 3. | Silexion Therapeutics Corp | $1.08 | — | $3.63 M | — | -260.98% | 1718.9% | $22.36 / $0.97 | $0.83 |
| 4. | OmniAb, Inc. | $1.55 | — | $237.44 M | — | -24.23% | -23.36% | $2.29 / $1.22 | $1.85 |
| 5. | Spero Therapeutics, Inc. | $2.84 | 19.18 | $164.41 M | — | 11.92% | 16.3% | $3.22 / $0.57 | $1.05 |
| 6. | NRx Pharmaceuticals, Inc. | $3.2 | — | $105.82 M | — | 103.85% | 146.18% | $3.84 / $1.62 | $-0.5 |
| 7. | Zura Bio Limited | $5.37 | — | $491.42 M | — | -74.11% | -52.49% | $7.44 / $0.98 | $1.38 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -10.48 M | -6.87 M | -7.29 M | -9.54 M | -15.57 M | — |
| Net Profit | -82.89 M | -6.61 M | -6.97 M | -9.14 M | -15 M | — |
| EPS in Rs | -8.82 | -0.7 | -0.74 | -0.97 | -1.6 | -7.46 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -34.18 M | -96.78 M | -126.94 M | -88.86 M |
| Net Profit | -105.61 M | -96.94 M | -117.67 M | -95.64 M |
| EPS in Rs | -11.24 | -10.32 | -12.53 | -10.18 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 92.15 M | 58.78 M | 160.25 M | 258.15 M |
| Total Liabilities | 64.36 M | 13.94 M | 30.06 M | 23.02 M |
| Equity | 27.79 M | 44.84 M | 130.19 M | 235.14 M |
| Current Assets | 89.46 M | 54.84 M | 154.73 M | 207.53 M |
| Current Liabilities | 47.5 M | 13.13 M | 28.84 M | 21.43 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -45.73 M | -97.17 M | -100.75 M | -72.47 M |
| Investing CF | -15.89 M | 54.83 M | 95.09 M | 57.66 M |
| Financing CF | 82.46 M | 0.19 M | 0.49 M | 0.65 M |
| Free CF | -45.73 M | -97.2 M | -101.06 M | -73.61 M |
| Capex | — | -0.03 M | -0.3 M | -1.14 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 17.62% | -23.04% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-09-18 | 1:0.1 |